dendreon ranked highest in sales growth, page-18

Horry,

The other point I forgot to mention in my reply to you was that US analysts put a $100 target on Dendreon based on the recent affirmation that Medicare would cover the full treatment cost for patients of $93,000 each.
__________

The other point worth a mention from the link provided is that Dendreon only targeted the US first with Provenge and haven't to my knowledge received any approvals from other due restrictions for commercialisation Provenge as yet.

"A reasonable projection for Provenge is 30-50% of the US market. This gives an estimate for eventual annual sales of Provenge in the U.S. between $800 million and $1.4 billion."

"Overseas markets will likely be 1-2 times the market in the U.S., which puts worldwide sales for Provenge in the wide $1.6 - $4.2 billion range, the upper end of which requires 50% market penetration in the U.S. and huge international sales."

Whilst as we've already been advised Prima have already proactively targeted Japan, Europe, US, NZ and Australia.

It would be great if we had more information to calculate future earnings for CVac based on area of coverage for the unmet market.

Provenge US figures have been calculated at 50% of the market due to both Medivation and Johnson & Johnson both in Phase 2 trials for the treatment of advanced prostate cancer. Johnson & Johnson are expecting to receive FDA approval in June this year.